MedTrace Logo

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

NCT00477035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-01-11

No results posted yet for this study

Summary

The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with high-risk hematologic malignancies.

Conditions

Interventions

DRUG

CIK cells

2x10e8 cells/kg

DRUG

etoposide

60 mg/kg

DRUG

bcnu

15 mg/kg

DRUG

cyclophosphamide

100 mg/kg

DRUG

gemcitabine

1250 mg/m2

DRUG

vinorelbine

30 mg/m2

DRUG

melphalan

200 mg/m2

Sponsors & Collaborators

  • Sally Arai

    lead OTHER

Principal Investigators

  • Sally Arai · Stanford University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477035 on ClinicalTrials.gov